Log in | Register

Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study

R. Moreno| C. L. Sprung| D. Annane| S. Chevret| J. Briegel| D. Keh| M. Singer| Y. G. Weiss| D. Payen| B. H. Cuthbertson| J.-L. Vincent
Original
Volume 37, Issue 11 / November , 2011

Pages 1765 - 1772

Abstract

Introduction

Corticosteroids have been proposed to decrease morbidity and mortality in patients with septic shock. An impact on morbidity should be anticipated to be earlier and more easily detected than the impact on mortality.

Methods

Prospective, randomized, double-blind, placebo-controlled study of 28-day mortality in patients with septic shock for <72 h who underwent a short high-dose ACTH test in 52 centers in 9 European countries. Patients received 11-day treatment with hydrocortisone or placebo. Organ dysfunction/failure was quantified by the use of the sequential organ failure assessment (SOFA) score.

Results

From March 2002 to November 2005, 499 patients were enrolled (hydrocortisone 251, placebo 248). Both groups presented a similar SOFA score at baseline (hydrocortisone 10.8 ± 3.2 vs. placebo 10.7 ± 3.1 points). There was no difference in 28-day mortality between the two treatment groups (hydrocortisone 34.3% vs. placebo 31.5%). There was a decrease in the SOFA score of hydrocortisone-treated patients from day 0 to day 7 compared to the placebo-treated patients (p = 0.0027), driven by an improvement in cardiovascular organ dysfunction/failure (p = 0.0005) and in liver failure (p < 0.0001) in the hydrocortisone-treated patients.

Conclusion

Patients randomized to treatment with hydrocortisone demonstrated a faster decrease in total organ dysfunction/failure determined by the SOFA score, primarily driven by a faster improvement in cardiovascular organ dysfunction/failure. This organ dysfunction/failure improvement was not accompanied by a decreased mortality.

Keywords

References

  1. Petros AJ, Marshall JC, van-Saene HK (1995) Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 345:369–371
    • View reference on PubMed
    • View reference on publisher's website
  2. Knaus WA, Wagner DP, Harrell FE, Draper EA (1994) What determines prognosis in sepsis? Evidence for a comprehensive individual patient risk assessment approach to the design and analysis of clinical trials. In: Reinhart K, Eyrich K, Sprung C (eds) Sepsis current perspectives in pathophysiology and therapy. Springer-Verlag, Berlin Heidelberg, pp 23–37
  3. Le Gall J-R, Lemeshow S, Leleu G, Klar J, Huillard J, Rué M, Teres D, Artigas A (1995) Customized probability models for early severe sepsis in adult intensive care patients. JAMA 273:644–650
    • View reference on PubMed
    • View reference on publisher's website
  4. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CD Jr, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
    • View reference on PubMed
    • View reference on publisher's website
  5. Vincent J-L, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G III, Bernard GR, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834–840
    • View reference on PubMed
    • View reference on publisher's website
  6. Carlet J (2006) Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med 34:525–529
    • View reference on PubMed
    • View reference on publisher's website
  7. Marshall JC, Vincent JL, Guyatt G, Angus DC, Abraham E, Bernard G, Bombardier C, Calandra T, Jørgensen HS, Sylvester R, Boers M (2005) Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the international sepsis forum. Crit Care Med 33:1708–1716
    • View reference on PubMed
    • View reference on publisher's website
  8. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301–1308
    • View reference on publisher's website
  9. Lilja HE, Leppäniemi A, Kemppainen E (2008) Utilization of intensive care unit resources in severe acute pancreatitis. JOP 8:179–184
  10. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre P-F, Reinhart K, Cuthbertson BH, Payen D, Briegel J, for the CORTICUS Study Group (2008) Hydrocortisone Therapy for Patients with Septic Shock. N Engl J Med 358:111–124
    • View reference on PubMed
    • View reference on publisher's website
  11. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
    • View reference on PubMed
    • View reference on publisher's website
  12. Vincent J-L, Moreno R, Takala J, Willats S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707–710
  13. Moreno R, Vincent J-L, Matos R, Mendonça A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S, on behalf of the Working Group on “Sepsis-related problems” of the European Society of Intensive Care Medicine (1999) The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Intensive Care Med 25:686–696
  14. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38(4):963–974
    • View reference on PubMed
    • View reference on publisher's website
  15. Lipsitz SH, Kim K, Zhao L (1994) Analysis of repeated categorical data using generalized estimating equations. Stat Med 13:1149–1163
    • View reference on PubMed
    • View reference on publisher's website
  16. Briegel J, Forst H, Haller M, Schelling G, Kilger E, JKuprat G, Hemmer B, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732
    • View reference on PubMed
    • View reference on publisher's website
  17. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach J-M, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
    • View reference on PubMed
    • View reference on publisher's website
  18. Bollaert PE (2000) Stress doses of glucocorticoids in catecholamine dependency: a new therapy for a new syndrome? Intensive Care Med 26:3–5
  19. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk H-D, Doecke W-D, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of “Low-Dose” hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512–520
    • View reference on PubMed
    • View reference on publisher's website
  20. Saito T, Takanashi M, Gallagher E, Fuse A, Suzaki S, Inagaki O, Yamada K, Ogawa R (1995) Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med 21:204–210
  21. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-Analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47–56
    • View reference on PubMed
  22. Hayashi Y, Takayama T, Yamazaki S, Moriguchi M, Ohkubo T, Nakayama H, Higaki T (2011) Validation of perioperative steroids administration in liver resection: a randomized controlled trial. Ann Surg 253:50–55
    • View reference on PubMed
    • View reference on publisher's website
  23. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent J-L (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement